Tech Company Financing Transactions
Eliem Therapeutics Funding Round
On 5/25/2021, Eliem Therapeutics raised $60 million in investment from Intermediate Capital Group, Access Industries and Acorn Bioventures.
Transaction Overview
Company Name
Announced On
5/25/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Investors
Intermediate Capital Group (Lead Investor)
RA Capital (Andrew Levin)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
23515 NE Novelty Hill Rd. B221 #125
Redmond, WA 98053
USA
Redmond, WA 98053
USA
Phone
Undisclosed
Website
Email Address
Overview
At its core, Eliem is motivated by the promise of helping people live happier, more fulfilling lives. The Eliem team channels its experience, energy and passion for improving patients' quality of life by developing life-changing novel therapies for neuronal excitability disorders based on clinically validated mechanisms of action.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Azelby
Chief Medical Officer
Amy Chappell
Chief Operating Officer
Erin Lavelle
VP - Bus. Development
Jo Palmer-Phillips
VP - General Counsel
James Bucher
VP - R & D
Valerie Morisset
Browse more venture capital transactions:
Prev: 5/25/2021: Future Family venture capital transaction
Next: 5/25/2021: Aurora Solar venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs